How Does DOCS Stock Compare With Its Peers Right Now?
Here is how Doximity (DOCS) stacks up against its peers in size, valuation, growth and margin.
- DOCS has the highest operating margin among peers at 40.3%.
- DOCS’s revenue growth of 20.0% in the last 12 months is solid, outpacing CACI, SAIC, LNW, CLVT, OTEX.
- DOCS gained 159.5% in the past year and trades at a PE of 56.2, outperforming its peers.
| DOCS | CACI | SAIC | LNW | CLVT | OTEX | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 12.5 | 11.0 | 5.6 | 6.7 | 2.6 | 7.6 |
| Revenue ($ Bil) | 0.6 | 8.4 | 7.5 | 3.2 | 2.5 | 5.2 |
| PE Ratio | 56.2 | 23.1 | 15.7 | 19.9 | -3.9 | 11.6 |
| LTM Revenue Growth | 20.0% | 14.2% | 3.4% | 7.3% | -3.5% | -11.5% |
| LTM Operating Margin | 40.3% | 9.0% | 7.3% | 24.3% | 8.9% | 19.5% |
| LTM FCF Margin | 46.8% | 5.8% | 6.1% | 11.1% | 14.1% | 13.6% |
| 12M Market Return | 159.5% | 7.4% | -2.9% | -22.9% | -32.2% | 6.8% |
Doximity operates a cloud-based digital platform for U.S. medical professionals, primarily serving pharmaceutical companies and health systems.
Why does this matter? DOCS just went up 16.1% in a week – peer comparison puts stock performance, valuation, and financials in context – highlighting whether it is truly outperforming, lagging behind, and above all – can this continue? Read Buy or Sell DOCS Stock to see if Doximity holds up as a quality investment. Furthermore, there is always a risk of fall after a strong rally – see how the stock has dipped and recovered in the past through DOCS Dip Buyer Analysis lens.
While peer comparison is critical Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risks while giving upside exposure.
Revenue Growth Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| DOCS | 20.0% | 20.0% | 13.5% | 22.0% | |
| CACI | 14.2% | – | 14.3% | 8.1% | 2.6% |
| SAIC | 3.4% | 0.5% | -3.4% | 4.2% | |
| LNW | 7.3% | – | 9.9% | 15.5% | 16.7% |
| CLVT | -3.5% | – | -2.7% | -1.2% | 41.7% |
| OTEX | -11.5% | – | 28.6% | 28.4% | 3.2% |
Operating Margin Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| DOCS | 40.3% | 40.3% | 36.1% | 29.9% | |
| CACI | 9.0% | – | 8.5% | 8.5% | 8.0% |
| SAIC | 7.3% | 7.5% | 6.7% | 6.7% | |
| LNW | 24.3% | – | 23.9% | 21.0% | 16.7% |
| CLVT | 8.9% | – | 9.1% | 10.4% | 10.0% |
| OTEX | 19.5% | – | 17.7% | 15.3% | 19.8% |
PE Ratio Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| DOCS | 49.0 | 44.7 | 36.1 | 57.5 | |
| CACI | 17.2 | – | 21.5 | 19.5 | 19.2 |
| SAIC | 15.1 | 15.5 | 13.8 | 20.4 | |
| LNW | 21.9 | – | 22.9 | 45.8 | 1.5 |
| CLVT | -4.5 | – | -5.5 | -6.8 | -1.4 |
| OTEX | 10.1 | – | 16.5 | 75.5 | 20.2 |
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.